Sacituzumab Govitecan is a targeted medication known as an antibody-drug conjugate. It works by delivering chemotherapy directly to cancer cells that express a specific protein found in bladder cancer. This medication helps to destroy cancer cells while limiting damage to healthy cells.

Zimberelimab is an immunotherapy medication that belongs to a class of drugs called PD-1 inhibitors. It works by helping your immune system recognize and fight cancer cells. This medication removes the “brakes” that cancer cells put on your immune system, allowing it to attack the tumor more effectively.

These medications are used together in this trial to treat muscle-invasive bladder cancer in patients who cannot receive cisplatin chemotherapy or do not wish to undergo surgery to remove their bladder.

Muscle-Invasive Bladder Cancer – A form of bladder cancer where cancer cells have grown through the bladder’s muscle wall. The cancer begins in the inner lining of the bladder and progressively spreads into the thick muscle layer of the bladder wall. This condition typically develops from non-muscle-invasive bladder cancer that has progressed deeper into the bladder tissues. The cancer cells can continue to grow and potentially spread to nearby organs and lymph nodes. As the disease progresses, it may cause symptoms such as blood in urine, frequent urination, and pelvic pain.